No. [ref] | Sex | Age (year) | Primary site | Histological type | TNM classification | Differentiation | Serum Ca | Leukocyte (/μL) | Serum PTHrP (pmol/L) (normal range) | Serum G-CSF (pg/mL) (normal range) | Main metastases | Outcome |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 [8] | Female | 65 | Thyroid gland | Anaplastic carcinoma | – | – | 13.8 | 142,000 | 4.02 (<1.1) | 318 (<30) | Cervix, lung, liver | death |
2 [9] | Male | 48 | Tonsil | SCC | – | – | 11.4 | 62,100 | 533.3 (<55.3) | 3450 (<30) | Cervix, lung, liver, | Death |
3 [10] | Female | 63 | Thyroid gland | Follicular and papillary carcinoma | T2N1bM1 | Well | 13.4 | 34,700 | 3.9 | 196 | Lung, bone | Death |
4 [11] | Male | 73 | Buccal mucosa | SCC | T4N3M1 | Poor | 15.1 | 40,200 | 108.5 (<55.3) | 1800 (<30) | Lung | Death |
5 [11] | Male | 60 | Gingiva | SCC | T4N2M0 | Well | 18.1 | 15,800 | 227.9 (<55.3) | 34.3 (<30) | Bone, lung | Death |
6 [11] | Male | 82 | Tongue | SCC | T3N2M0 | Poor | 14.7 | 79,000 | 132 (<55.3) | 274 (<30) | Lung | Death |
7 [11] | Male | 65 | Buccal mucosa | SCC | T4N2M0 | Poor | 16.2 | 34,600 | 255 (<55.3) | 211 (<30) | Lung, liver, pancreas | Death |
8 [12] | Male | 61 | Tongue | SCC | T1N0MX | Well | 28.5 | 31,300 | 3109 (<16) [pg/mL] | 285 (<20) (pleural fluid) | Cervix, lung | Death |
9 [13] | Male | 65 | Larynx | SCC | T4N3M0 | – | 18 | 60,000 | 5.6 (<0.5) | 222 (<38) | Cervix, lung | Death |
10 [14] | Female | 57 | Hypopharynx | SCC | T3N2bMX | Poor | 14.2 | 46,300 | 12.4 (<1.1) | 111 (<39) | Cervix, lung, liver, bone, kidney, skin | Death |
11 [15] | Female | 32 | Mandible | Ameloblastoma | – | – | 11.3 | 37,200 | 14.7 (<1.1) | 68 (<30) | – | Survive |
12 [16] | Male | 76 | Hypopharynx | SCC | T4aN2cM0 | Moderate | 11.2 | 20,230 | 3.1 (<1.1) | 213 (<39) | Cervix, esophagus | Survive |
Present case | Male | 57 | Tongue | SCC | T4aN0M0 | Moderate | 16.3 | 22,770 | 12.2 (<1.1) | 60 (<39) | Cervix, lung, bone, femur, adrenal gland, groin | Death |